Efficacy of cetuximab for preventing progression of CRC liver metastases after selective portal embolisatio
- Conditions
- Patients with colorectal cancer and livermetastases planned for hemihepatectomy following portal embolisation
- Registration Number
- EUCTR2007-000973-41-SE
- Lead Sponsor
- Karolinska University Hospital, Huddinge
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Liver met of CRC
Planned for hemihepatectomy following portal embolisation of the ipsilateral liver lobe and expansion of the contralateral liver lobe.
Medically fit for hemihepatectomy
Responder to downsizing combination chemotherapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Extrahepatic CRC lesions
Known allergy to cetuximab
Previous exposure to cetuximab
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method